18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer

Oncotarget
Jingyi ChengDaoying Geng

Abstract

The aim of this prospective study was to assess the ability of 18F-fluorodeoxyglucose ((18)FDG) positron emission tomography/computed tomography (PET/CT) scanning to predict pathological complete response (pCR) in breast cancer, and to investigate whether timing of the scan and trastuzumab treatment influence the accuracy of pCR prediction in human epidermal growth factor receptor 2 (HER2) positive breast cancer patients. We treated 81 locally advanced breast cancer patients with four cycles of neoadjuvant chemotherapy (NAC). HER2-negative breast cancer patients received NAC alone, while HER2-positive breast cancer patients received NAC plus trastuzumab. (18)FDG PET/CT scans were scheduled at baseline and after the second cycle of NAC. Axillary lymph node (ALN) dissection was performed after the last cycle of neoadjuvant therapy. Relative changes in standardized uptake values (SUV) between the two PET/CT scans (ΔSUV) in primary tumors and ALN metastases were calculated. There were 75 patients with 150 PET/CT scans in the final analysis, including 41 HER2-negative and 34 HER2-positive cases. In the HER2-negative group, the ΔSUV predicted overall and ALN pCR; the receiver operating characteristics-areas under curve (ROC-AUC) were...Continue Reading

References

Apr 14, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M SchellingM Schwaiger
Feb 3, 2005·Journal of the National Cancer Institute·Davide MauriJohn P A Ioannidis
Nov 8, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Caroline RousseauMario Campone
Feb 9, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Priya RastogiNorman Wolmark
Jul 9, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Chirayu ShahH Charles Manning
Feb 5, 2010·European Journal of Nuclear Medicine and Molecular Imaging·Marieke E StraverMarie-Jeanne T F D Vrancken Peeters
Feb 11, 2011·European Journal of Nuclear Medicine and Molecular Imaging·Caroline RousseauFrançoise Kraeber-Bodéré
Apr 14, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·O HumbertF Brunotte
Nov 6, 2012·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·Y MachidaH Shibuya
Jan 19, 2013·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Mathieu HattCatherine Cheze-Le Rest
Feb 19, 2013·The Breast : Official Journal of the European Society of Mastology·Bas B KoolenRenato A Valdés Olmos
Oct 5, 2013·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Geraldine GebhartSerena Di Cosimo

❮ Previous
Next ❯

Citations

Apr 25, 2019·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging·Oke GerkeWerner Vach

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
dissection

Software Mentioned

HercepTest
TrueD

Related Concepts

Related Feeds

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

© 2021 Meta ULC. All rights reserved